Concentrix Corporation (CNXC)

Concentrix’s FY2025 GAAP loss was largely impairment-driven (goodwill write-down tied to the Webhelp deal), but cash generation remained positive (FY2025 free cash flow about $572M). The May-2026 10-Q reports covenant compliance and substantial liquidity capacity, yet leverage is still high (net debt about $4.31B) and distress indicators are weak (Altman Z-score ~0.80; interest coverage ~1.77x). Valuation screens very cheap on EV/Sales (~0.58) and free-cash-flow yield (~35.94%), with analyst consensus target around $35 vs $23.42. Overall: mixed setup—value upside, but elevated integration and balance-sheet risk (score 3/5).

CNXC’s near-term narrative is still dominated by the 2026-06-29 Q2 results (confidence: announced), which third-party coverage framed as an earnings miss and weak guidance, keeping the last ~14d media tone negative-leaning. Baseline sentiment is indeterminate (baseline <3 items), the legal screen is clean, but a moderate red-flag applies: sharp post-earnings sentiment deterioration with no clear near-term bullish catalyst (caps score at 3).

CNXC meets the price cap, liquidity floor, and event-calendar requirements, but the chart is not yet long-ready. The stock remains below its 20/50/200-day SMAs, below EMA9/21, and below the latest daily VWAP, while MACD is below both its signal line and zero. ADX above 30 confirms that a trend is present, but price location shows it is still a bearish trend, not a bullish one. RSI 43.34 and Williams %R -48.07 are only neutral, so the post-earnings selloff is no longer deeply oversold yet still lacks reversal confirmation.